NOT-AI-13-033: Notice of Clarification and Correction to RFA-AI-12-059 Autoimmunity Centers of Excellence, Clinical Research Program (UM1)

Notice of Clarification and Correction to RFA-AI-12-059 Autoimmunity Centers of Excellence, Clinical Research Program (UM1)

Notice Number: NOT-AI-13-033

Key Dates
Release Date: March 15, 2013

Related Announcements
RFA-AI-12-059

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice clarifies the type of permissible pre-competition collaborations within the Clinical Projects, which are required in a Clinical Autoimmunity Centers of Excellence (ACE) UM1 application.

A Clinical Project may NOT be shared between applications to this FOA. If two applications propose the same Clinical Project, both applications may be deemed non-responsive and will not be reviewed. Applicants may propose collaborations with other investigators (who may also be applicants), but the complete Clinical Project must be contained within a single application.

This Notice also corrects the language in the 'Funding Opportunity Purpose' section of the FOA.

CURRENT LANGUAGE:
This FOA solicits applications to participate in the Autoimmunity Centers of Excellence (ACE) program, a cooperative network intended to improve the understanding and treatment of autoimmune diseases (www.autoimmunitycenters.org). The ACE program was founded on the premise that collaboration among basic and clinical scientists can accelerate both fundamental and applied research. For this reissuance, the formerly integrated Centers are divided into Basic and Clinical research programs. This FOA solicits applications for the Clinical research program; a companion FOA solicits applications for the Basic research program. The members of the Basic and Clinical ACE will work together to design and conduct studies of mechanisms of action of immune-modulating agents tested in clinical trials.

A program director/principal investigator (PD/PI) may NOT apply to both this ACE Clinical program FOA and the companion Basic program FOA.

NEW LANGUAGE:
This FOA solicits applications to participate in the Autoimmunity Centers of Excellence (ACE) program, a cooperative network intended to improve the understanding and treatment of autoimmune diseases (www.autoimmunitycenters.org). The ACE program was founded on the premise that collaboration among basic and clinical scientists can accelerate both fundamental and applied research. For this reissued FOA, the formerly integrated Centers are divided into Basic and Clinical research programs. This FOA solicits applications for the Clinical research program; a companion FOA solicits applications for the Basic research program. The members of the Basic and Clinical ACE will work together to design and conduct studies of mechanisms of action of immune-modulating agents tested in clinical trials.

A program director/principal investigator (PD/PI) may NOT apply to both this ACE Clinical program FOA and the companion Basic program FOA.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

David Johnson, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
6610 Rockledge Drive
Room 6714-B
Bethesda, MD 20892-6601
Telephone: 301-496-7104
Email: [email protected]